Vanguard Group’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $2.62B | Sell |
9,539,173
-165,775
| -2% | -$45.3M | 0.04% | 413 |
|
|
2025
Q3 | $2.55B | Buy |
9,704,948
+388,144
| +4% | +$94.3M | 0.04% | 422 |
|
|
2025
Q2 | $2.04B | Buy |
9,316,804
+85,083
| +0.9% | +$18.2M | 0.03% | 461 |
|
|
2025
Q1 | $2.07B | Buy |
9,231,721
+244,259
| +3% | +$67.3M | 0.04% | 447 |
|
|
2024
Q4 | $2.94B | Sell |
8,987,462
-1,509
| -0% | -$475K | 0.05% | 357 |
|
|
2024
Q3 | $2.7B | Buy |
8,988,971
+45,112
| +0.5% | +$13.8M | 0.05% | 374 |
|
|
2024
Q2 | $2.95B | Buy |
8,943,859
+4,392
| +0% | +$1.55M | 0.06% | 330 |
|
|
2024
Q1 | $3.54B | Sell |
8,939,467
-63,165
| -0.7% | -$23.4M | 0.07% | 292 |
|
|
2023
Q4 | $3.17B | Buy |
9,002,632
+104,740
| +1% | +$37.1M | 0.07% | 299 |
|
|
2023
Q3 | $3.34B | Sell |
8,897,892
-52,720
| -0.6% | -$20.4M | 0.08% | 246 |
|
|
2023
Q2 | $3.42B | Buy |
8,950,612
+17,303
| +0.2% | +$6.18M | 0.08% | 249 |
|
|
2023
Q1 | $3.1B | Sell |
8,933,309
-55,100
| -0.6% | -$16.1M | 0.08% | 268 |
|
|
2022
Q4 | $2.12B | Buy |
8,988,409
+62,444
| +0.7% | +$14.8M | 0.06% | 375 |
|
|
2022
Q3 | $2.2B | Buy |
8,925,965
+92,870
| +1% | +$28.3M | 0.06% | 327 |
|
|
2022
Q2 | $2.67B | Buy |
8,833,095
+116,783
| +1% | +$38M | 0.08% | 276 |
|
|
2022
Q1 | $3.58B | Buy |
8,716,312
+82,459
| +1% | +$32.3M | 0.08% | 239 |
|
|
2021
Q4 | $4.05B | Buy |
8,633,853
+103,494
| +1% | +$44.5M | 0.09% | 210 |
|
|
2021
Q3 | $3.62B | Buy |
8,530,359
+141,824
| +2% | +$59.8M | 0.09% | 216 |
|
|
2021
Q2 | $3.01B | Sell |
8,388,535
-75,950
| -0.9% | -$25.1M | 0.08% | 282 |
|
|
2021
Q1 | $2.39B | Buy |
8,464,485
+175,115
| +2% | +$50.1M | 0.06% | 336 |
|
|
2020
Q4 | $2.35B | Sell |
8,289,370
-317,920
| -4% | -$89.2M | 0.07% | 311 |
|
|
2020
Q3 | $2.37B | Sell |
8,607,290
-12,897
| -0.1% | -$3.41M | 0.08% | 252 |
|
|
2020
Q2 | $1.96B | Buy |
8,620,187
+938,852
| +12% | +$184M | 0.07% | 299 |
|
|
2020
Q1 | $1.17B | Buy |
7,681,335
+182,222
| +2% | +$28M | 0.05% | 393 |
|
|
2019
Q4 | $1.13B | Buy |
7,499,113
+105,736
| +1% | +$15.4M | 0.04% | 511 |
|
|
2019
Q3 | $1.05B | Buy |
7,393,377
+73,039
| +1% | +$10.1M | 0.04% | 503 |
|
|
2019
Q2 | $916M | Sell |
7,320,338
-29,122
| -0.4% | -$3.44M | 0.03% | 548 |
|
|
2019
Q1 | $810M | Buy |
7,349,460
+47,872
| +0.7% | +$4.98M | 0.03% | 573 |
|
|
2018
Q4 | $716M | Buy |
7,301,588
+233,859
| +3% | +$25.4M | 0.03% | 566 |
|
|
2018
Q3 | $873M | Buy |
7,067,729
+139,098
| +2% | +$15.6M | 0.03% | 563 |
|
|
2018
Q2 | $688M | Buy |
6,928,631
+104,171
| +2% | +$9.59M | 0.03% | 626 |
|
|
2018
Q1 | $603M | Buy |
6,824,460
+36,177
| +0.5% | +$3.38M | 0.03% | 662 |
|
|
2017
Q4 | $670M | Buy |
6,788,283
+101,285
| +2% | +$9.93M | 0.03% | 622 |
|
|
2017
Q3 | $644M | Buy |
6,686,998
+131,647
| +2% | +$11.9M | 0.03% | 613 |
|
|
2017
Q2 | $620M | Buy |
6,555,351
+114,507
| +2% | +$10.5M | 0.03% | 608 |
|
|
2017
Q1 | $526M | Buy |
6,440,844
+392,516
| +6% | +$32.8M | 0.03% | 676 |
|
|
2016
Q4 | $513M | Buy |
6,048,328
+152,646
| +3% | +$12M | 0.03% | 644 |
|
|
2016
Q3 | $439M | Buy |
5,895,682
+180,951
| +3% | +$14.4M | 0.03% | 674 |
|
|
2016
Q2 | $434M | Buy |
5,714,731
+194,455
| +4% | +$14.2M | 0.03% | 661 |
|
|
2016
Q1 | $383M | Buy |
5,520,276
+198,928
| +4% | +$12M | 0.02% | 692 |
|
|
2015
Q4 | $320M | Buy |
5,321,348
+46,295
| +0.9% | +$2.79M | 0.02% | 756 |
|
|
2015
Q3 | $285M | Sell |
5,275,053
-389,452
| -7% | -$22.7M | 0.02% | 787 |
|
|
2015
Q2 | $329M | Buy |
5,664,505
+132,210
| +2% | +$7.38M | 0.02% | 766 |
|
|
2015
Q1 | $333M | Buy |
5,532,295
+32,711
| +0.6% | +$1.74M | 0.02% | 761 |
|
|
2014
Q4 | $293M | Buy |
5,499,584
+192,217
| +4% | +$9.61M | 0.02% | 768 |
|
|
2014
Q3 | $238M | Sell |
5,307,367
-327,003
| -6% | -$13.9M | 0.02% | 843 |
|
|
2014
Q2 | $238M | Buy |
5,634,370
+93,403
| +2% | +$4M | 0.02% | 870 |
|
|
2014
Q1 | $244M | Buy |
5,540,967
+142,573
| +3% | +$6.71M | 0.02% | 834 |
|
|
2013
Q4 | $265M | Buy |
5,398,394
+307,073
| +6% | +$14.4M | 0.02% | 755 |
|
|
2013
Q3 | $210M | Buy |
5,091,321
+425,085
| +9% | +$16.2M | 0.02% | 815 |
|
|
2013
Q2 | $164M | Buy |
+4,666,236
| New | +$154M | 0.02% | 884 |
|
Other funds holding WST
GIM
LP
Vanguard Group's WST Position: Q4 2025 in Review
Vanguard Group reduced its West Pharmaceutical (WST) stake by 1.7% in Q4 2025, selling an estimated $45.3M and leaving 9,539,173 shares worth $2.62B. The position accounts for 0.04% of the portfolio, ranked #413.
Vanguard Group first reported a position in WST in Q2 2013 and has held it in 51 quarters since. The position peaked at $4.05B in Q4 2021. 802 funds tracked by Wall St. Rank hold WST as of Q4 2025.
- Vanguard Group held 9,539,173 shares of West Pharmaceutical worth $2.62B as of Q4 2025.
- Vanguard Group sold 165,775 West Pharmaceutical shares in Q4 2025, an estimated $45.3M.
- West Pharmaceutical made up 0.04% of Vanguard Group's portfolio in Q4 2025, its #413 holding.
- Vanguard Group first reported a position in West Pharmaceutical in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's West Pharmaceutical position peaked at $4.05B in Q4 2021.
- 802 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.